Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety, Tolerability, and Pharmacokinetics of KD6001 in Patients With Advanced Solid Tumours - Phase I Clinical Study

NCT05230290 is registered in ClinicalTrials.gov with Shanghai Kanda Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05230290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05230290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety, Tolerability, and Pharmacokinetics of KD6001 in Patients With Advanced Solid Tumours - Phase I Clinical Study
Lead sponsor
Shanghai Kanda Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 10, 2020
Completion date
July 26, 2022
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor